xanomeline has been researched along with donepezil in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Palacios, JM | 1 |
Cannon, CE; Dancho, M; Koser, A; Kuduk, SD; Puri, V; Renger, JJ; Uslaner, JM; Vardigan, JD; Wittmann, M | 1 |
Kimura, H; Kurimoto, E; Nakashima, M; Suzuki, M | 1 |
3 other study(ies) available for xanomeline and donepezil
Article | Year |
---|---|
Alzheimer's disease: new pharmacological perspectives.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Humans; Indans; Muscarinic Agonists; Oximes; Phenylcarbamates; Piperidines; Pyridines; Rivastigmine; Tacrine; Thiadiazoles | 1996 |
Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
Topics: Aged; Alzheimer Disease; Animals; Appetitive Behavior; Attention; Cognition; Defecation; Donepezil; Female; Humans; Indans; Macaca mulatta; Male; Muscarinic Agonists; Neuropsychological Tests; Orientation; Piperidines; Problem Solving; Pyridines; Quinolizines; Receptor, Muscarinic M1; Salivation; Thiadiazoles | 2015 |
TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys.
Topics: Allosteric Regulation; Alpha Rhythm; Animals; Delta Rhythm; Donepezil; Dose-Response Relationship, Drug; Electroencephalography; Macaca fascicularis; Muscarinic Agonists; Pyridines; Receptor, Muscarinic M1; Scopolamine; Theta Rhythm; Thiadiazoles | 2019 |